Matrixx Initiatives Inc. (Zicam), Scottsdale, AZ 483 issued 5/28/2009 (1 page)
Similar Posts
FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).Novel Drug Approvals for 2022
Innovative drugs often mean new treatment options for patients and advances in health care for the American public.Replacing and Reducing Animal Testing at CDER
It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.Consumer Updates
Science-based health and safety information you can trust.www.usmedschoice.com – 716055 – 10/06/2025
Unapproved New Drugs/Misbranded
